InsidersTradesSigma
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
无可用的信号评分。
Discover the detailed record of transactions filed by Huber Reid M, 董事. Director active across 4 companies, notably Bellicum Pharmaceuticals, INC. Aggregated, 7 filings have been logged. Split: 1 buy · 0 sell. Total volume traded: €426k. History available since 4 January 2022. The latest transaction was filed on 12 September 2025 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 条申报中的 7 条
Huber Reid M is Administrateur at Bellicum Pharmaceuticals, INC, Rapport Therapeutics, Inc. and Tango Therapeutics, Inc., and EVP, Chief Scientific Officer at INCYTE CORP. He has 7 filings in total, and across the sampled recent filings between 2016-01-08 and 2025-09-15, the buy volume is EUR 425551 and the most frequent transaction nature is option exercise.